Anti-interleukin IL-1 Receptor Antagonist (ANAKINRA) for the Treatment of Severe COVID-19 Pneumonia and Hyperinflammatory Syndrome in Patients Admitted at SQUH

Study Protocol

Admitted adult patients [Age > 18 years] with COVID-19 AND any of the following

1. Severe pneumonia:

Pneumonia PLUS respiratory rate > 30 breaths/min OR SpO2 < 90% on room air or 93% or less under oxygen 6 L/min or more in addition to signs indicative of worsening respiratory function.

OR


2. Acute respiratory distress syndrome (ARDS):

Pneumonia PLUS bilateral opacities (on CXR or CT) PLUS respiratory failure with PaO2/FiO2 ≤ 300 mmHg.

OR

3. Cytokine release syndrome:

Fever [> 39] PLUS multiorgan failure PLUS cytopenia PLUS IL-6 level >100 pg/ml OR single ferritin above 3000 mcg/L.



Obtain baseline CXR, FBC, Renal and Liver functions, CRP, LDH, D-dimer, serum Ferritin, IL-6. Call pharmacist Athar [71166859] for approval of the prescription of ANAKINRA and for dosing adjustment [if eGFR<30 and for patients on dialysis].

Follow up and safety monitoring for enrolled patients:

Repeat CRP, LDH, D-dimer, serum Ferritin, IL-6, FBC, Renal and Liver functions on **Day 4** and **Day 14**. Repeat CXR on **Day 14**.

Blood culture [ONLY if suspected sepsis].

Daily record of the following in the EPR [starting from Day 0]:

Fever, respiratory rate, oxygen saturation, oxygen requirement, need for NIV, IMV, and transfer to ICU.

Simplified Study Protocol. Prepared by **Dr Abdullah Balkhair**, Principal Investigator.